Literature DB >> 21796103

The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis.

Jonas Hannestad1, Nicole DellaGioia, Michael Bloch.   

Abstract

Serum levels of inflammatory cytokines, for example, tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and IL-1 beta (IL-1β), are elevated in subjects with major depressive disorder (MDD). The reason why this occurs is unclear. Elevated levels of inflammatory cytokines could be a result of brain dysfunction in MDD. It is also possible that inflammatory cytokines contribute to depressive symptoms in MDD. If the first assumption is correct, one would expect levels to normalize with resolution of the depressive episode after treatment. Several studies have measured changes in cytokine levels during antidepressant treatment; however, the results vary. The purpose of this study was to pool all available data on changes in serum levels of TNFα, IL-6, and IL-1β during antidepressant treatment to determine whether these levels change. Studies were included if they used an approved pharmacological treatment for depression, patients had a diagnosis of MDD, and serum levels of TNFα, IL-6, and/or IL-1β were measured before and after treatment. Twenty-two studies fulfilled these criteria. Meta-analysis of these studies showed that, overall, while pharmacological antidepressant treatment reduced depressive symptoms, it did not reduce serum levels of TNFα. On the other hand, antidepressant treatment did reduce levels of IL-1β and possibly those of IL-6. Stratified subgroup analysis by class of antidepressant indicated that serotonin reuptake inhibitors may reduce levels of IL-6 and TNFα. Other antidepressants, while efficacious for depressive symptoms, did not appear to reduce cytokine levels. These results argue against the notion that resolution of a depressive episode is associated with normalization of levels of circulating inflammatory cytokines; however, the results are consistent with the possibility that inflammatory cytokines contribute to depressive symptoms and that antidepressants block the effects of inflammatory cytokines on the brain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21796103      PMCID: PMC3194072          DOI: 10.1038/npp.2011.132

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  53 in total

1.  Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine.

Authors:  A Słuzewska; J K Rybakowski; M Laciak; A Mackiewicz; M Sobieska; K Wiktorowicz
Journal:  Ann N Y Acad Sci       Date:  1995-07-21       Impact factor: 5.691

2.  Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission.

Authors:  M Kubera; G Kenis; E Bosmans; A Zieba; D Dudek; G Nowak; M Maes
Journal:  Pol J Pharmacol       Date:  2000 May-Jun

Review 3.  Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression.

Authors:  Charles L Raison; Christopher A Lowry; Graham A W Rook
Journal:  Arch Gen Psychiatry       Date:  2010-12

4.  Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder.

Authors:  Shima Jazayeri; Seyed A Keshavarz; Mehdi Tehrani-Doost; Mahmood Djalali; Mostafa Hosseini; Homayoun Amini; Maryam Chamari; Abolghassem Djazayery
Journal:  Psychiatry Res       Date:  2010-05-13       Impact factor: 3.222

5.  Effects of behavioral stimuli on plasma interleukin-1 activity in humans at rest.

Authors:  W H Keppel; D H Regan; S H Heffeneider; S McCoy; F Ramsey
Journal:  J Clin Psychol       Date:  1993-11

Review 6.  Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.

Authors:  M Bryant Howren; Donald M Lamkin; Jerry Suls
Journal:  Psychosom Med       Date:  2009-02-02       Impact factor: 4.312

7.  Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.

Authors:  M Maes; E Bosmans; R De Jongh; G Kenis; E Vandoolaeghe; H Neels
Journal:  Cytokine       Date:  1997-11       Impact factor: 3.861

8.  The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.

Authors:  N Müller; M J Schwarz; S Dehning; A Douhe; A Cerovecki; B Goldstein-Müller; I Spellmann; G Hetzel; K Maino; N Kleindienst; H-J Möller; V Arolt; M Riedel
Journal:  Mol Psychiatry       Date:  2006-02-21       Impact factor: 15.992

9.  Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder.

Authors:  Cengiz Tuglu; S Hakan Kara; Okan Caliyurt; Erdal Vardar; Ercan Abay
Journal:  Psychopharmacology (Berl)       Date:  2003-08-30       Impact factor: 4.530

10.  Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression.

Authors:  Reiji Yoshimura; Hikaru Hori; Atsuko Ikenouchi-Sugita; Wakako Umene-Nakano; Nobuhisa Ueda; Jun Nakamura
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-03-28       Impact factor: 5.067

View more
  246 in total

Review 1.  Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?

Authors:  David Baumeister; Simone Ciufolini; Valeria Mondelli
Journal:  Psychopharmacology (Berl)       Date:  2015-08-14       Impact factor: 4.530

Review 2.  Inflammation: depression fans the flames and feasts on the heat.

Authors:  Janice K Kiecolt-Glaser; Heather M Derry; Christopher P Fagundes
Journal:  Am J Psychiatry       Date:  2015-09-11       Impact factor: 18.112

Review 3.  The Bidirectional Relationship of Depression and Inflammation: Double Trouble.

Authors:  Eléonore Beurel; Marisa Toups; Charles B Nemeroff
Journal:  Neuron       Date:  2020-06-17       Impact factor: 17.173

4.  Rapid Regulation of Depression-Associated Genes in a New Mouse Model Mimicking Interferon-α-Related Depression in Hepatitis C Virus Infection.

Authors:  Carolina Hoyo-Becerra; Zijian Liu; Jinghong Yao; Britta Kaltwasser; Guido Gerken; Dirk M Hermann; Joerg F Schlaak
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

Review 5.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

6.  Inflammatory markers and chronic exposure to fluoxetine, divalproex, and placebo in intermittent explosive disorder.

Authors:  Emil F Coccaro; Royce Lee; Elizabeth C Breen; Michael R Irwin
Journal:  Psychiatry Res       Date:  2015-07-29       Impact factor: 3.222

7.  Longitudinal association of inflammation with depressive symptoms: A 7-year cross-lagged twin difference study.

Authors:  Minxuan Huang; Shaoyong Su; Jack Goldberg; Andrew H Miller; Oleksiy M Levantsevych; Lucy Shallenberger; Pratik Pimple; Bradley Pearce; J Douglas Bremner; Viola Vaccarino
Journal:  Brain Behav Immun       Date:  2018-10-27       Impact factor: 7.217

8.  Modulatory Effects of Antidepressant Classes on the Innate and Adaptive Immune System in Depression.

Authors:  H A Eyre; H Lavretsky; J Kartika; A Qassim; B T Baune
Journal:  Pharmacopsychiatry       Date:  2016-03-07       Impact factor: 5.788

Review 9.  Psychoneuroimmunology of Early-Life Stress: The Hidden Wounds of Childhood Trauma?

Authors:  Andrea Danese; Stephanie J Lewis
Journal:  Neuropsychopharmacology       Date:  2016-09-15       Impact factor: 7.853

10.  Lipopolysaccharide-Induced Behavioral Alterations Are Alleviated by Sodium Phenylbutyrate via Attenuation of Oxidative Stress and Neuroinflammatory Cascade.

Authors:  Ashok Jangra; Chandra Shaker Sriram; Mangala Lahkar
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.